Ad is loading...
PRME
Price
$3.29
Change
+$0.32 (+10.77%)
Updated
Nov 22, 03:34 PM (EDT)
PROK
Price
$1.72
Change
-$0.02 (-1.15%)
Updated
Nov 22, 03:34 PM (EDT)
130 days until earnings call
Ad is loading...

PRME vs PROK

Header iconPRME vs PROK Comparison
Open Charts PRME vs PROKBanner chart's image
Prime Medicine
Price$3.29
Change+$0.32 (+10.77%)
Volume$1.89K
CapitalizationN/A
ProKidney
Price$1.72
Change-$0.02 (-1.15%)
Volume$318
CapitalizationN/A
PRME vs PROK Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PRME vs. PROK commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Buy and PROK is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (PRME: $2.97 vs. PROK: $1.74)
Brand notoriety: PRME and PROK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 53% vs. PROK: 33%
Market capitalization -- PRME: $389.55M vs. PROK: $222.66M
PRME [@Biotechnology] is valued at $389.55M. PROK’s [@Biotechnology] market capitalization is $222.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whilePROK’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • PROK’s FA Score: 0 green, 5 red.
According to our system of comparison, both PRME and PROK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while PROK’s TA Score has 3 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 5 bearish.
  • PROK’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, PRME is a better buy in the short-term than PROK.

Price Growth

PRME (@Biotechnology) experienced а -17.39% price change this week, while PROK (@Biotechnology) price change was -19.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.98%, and the average quarterly price growth was +4.01%.

Reported Earning Dates

PRME is expected to report earnings on Nov 13, 2024.

PROK is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($390M) has a higher market cap than PROK($223M). PROK YTD gains are higher at: -2.247 vs. PRME (-66.479). PROK has higher annual earnings (EBITDA): -131.07M vs. PRME (-207.13M). PROK has more cash in the bank: 407M vs. PRME (176M). PROK has less debt than PRME: PROK (6.44M) vs PRME (41.2M). PRME has higher revenues than PROK: PRME (800K) vs PROK (0).
PRMEPROKPRME / PROK
Capitalization390M223M175%
EBITDA-207.13M-131.07M158%
Gain YTD-66.479-2.2472,958%
P/E RatioN/AN/A-
Revenue800K0-
Total Cash176M407M43%
Total Debt41.2M6.44M640%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PRMEPROK
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
61%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
66%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
71%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFMAX34.870.32
+0.93%
Davidson Multi-Cap Equity A
IENYX32.550.23
+0.71%
Invesco Energy Y
FMUFX14.940.05
+0.34%
Federated Hermes Muni and Stock Adv F
JHDRX18.660.03
+0.16%
JPMorgan Hedged Equity 2 R6
VKSGX10.96N/A
N/A
Virtus KAR Small-Mid Cap Value R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-0.67%
BEAM - PRME
61%
Loosely correlated
-3.72%
NTLA - PRME
61%
Loosely correlated
+5.18%
CRSP - PRME
60%
Loosely correlated
-2.05%
ABCL - PRME
57%
Loosely correlated
+1.87%
RXRX - PRME
55%
Loosely correlated
-4.80%
More

PROK and

Correlation & Price change

A.I.dvisor tells us that PROK and BEAM have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PROK and BEAM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
+5.45%
BEAM - PROK
32%
Poorly correlated
-3.72%
PRME - PROK
32%
Poorly correlated
-0.67%
RXRX - PROK
31%
Poorly correlated
-4.80%
ADPT - PROK
29%
Poorly correlated
-1.13%
CRBU - PROK
29%
Poorly correlated
+1.02%
More